Navigation Links
Nektar Therapeutics Announces Second Quarter 2008 Results
Date:8/6/2008

quarter and first half of 2008 compared to a year ago is primarily the result of a loss of gross margin associated with Pfizer's termination of the Exubera collaboration and maintenance of Exubera manufacturing capacity through April 2008. The final spending and charges associated with the termination of the Exubera inhaled insulin program were paid and recorded in the second quarter of 2008.

"Over the past year, Nektar has made excellent progress in expanding and advancing our pipeline while at the same time maintaining financial discipline," said Nektar President and CEO Howard W. Robin. "In 2008, we will have seven proprietary programs in clinical development and an impressive preclinical pipeline of important, high-value therapeutics. We have executed on our strategy of building valuable proprietary programs without pursuing any dilutive financings."

Nektar will host a conference call today for analysts and investors at 2:00 p.m. Pacific time to discuss the company's second quarter performance. This conference call will be available via webcast and can be accessed through a link that is posted on the Investor Relations section of the Nektar website, http://www.nektar.com. The web broadcast of the conference call will be available for replay through August 20, 2008.

To access the conference call, follow these instructions:

Dial: (866) 831-5605 (U.S.); (617) 213-8851 (international)

Passcode: 33430853 (Howard Robin is the host)

Audio replay dial-in and passcode:

Dial: (888) 286-8010 (U.S.); (617) 801-6888 (international)

Passcode: 67859021

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
2. Nektar Therapeutics Announces First Quarter 2008 Results
3. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
4. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
5. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
6. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
7. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
8. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
9. Nektar Therapeutics Announces Third Quarter 2007 Financial Results
10. Nektar to Announce Third Quarter 2007 Financial Results on Wednesday, November 7, 2007, After the Close of U.S. Financial Markets
11. InteKrin Therapeutics Announces $20 Million Series C Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... Children who swallow high-powered magnets often need surgery and ... a new study. The researchers, from the Louisiana ... more than 79 percent of children who swallowed very ... procedure, in which a tube containing a camera is ... these cases can be treated through observation or by ...
(Date:5/18/2013)... 18, 2013) The use of a smartphone ... according to new research presented today at Digestive ... days in advance of the procedure, includes dietary ... be taken at strict intervals. The better the ... see cancer and precancerous polyps in the colon. ...
(Date:5/18/2013)... In a May 14, 2013 article entitled ... Discovering Cancer Gene,” Fox News reported the movie star ... she carried a gene that doctors estimated gave her ... 50 percent risk of ovarian cancer (go to: goo.gl/5JHBP). ... 2013 with a blog post entitled “A Patient’s Journey: ...
(Date:5/18/2013)... 18, 2013 Today, Zane Benefits, ... agents’ role in Marketplaces . Zane Benefits, which ... sponsored health benefits, is the leader in health ... health reimbursement arrangements . , According to Zane ... Services (HHS) recently released a much-anticipated statement and ...
(Date:5/18/2013)... Serena Gordon HealthDay Reporter , , FRIDAY, May 17 ... students sometimes binge drink, but new research shows that college ... on a weekly basis than are college men. ... alcohol that,s considered safe on a weekly basis is much ... for women versus 14 for men. But, there,s good reason ...
Breaking Medicine News(10 mins):Health News:Swallowing Magnets Can Be Fatal for Children 2Health News:New smartphone application improves colonoscopy preparation 2Health News:Angelina Jolie – Scarless Breast Augmentation Surgery 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:College Women More Prone to Problem Drinking Than Men: Study 2Health News:College Women More Prone to Problem Drinking Than Men: Study 3
... OxyContin in late 1995 and the drug was put ... and 2000, prescriptions for the drug have increased by ... powerful heroin-like high by crushing the pill and injecting, ... OxyContin, the nation's best selling prescription painkiller, began in ...
... eye’s retina is well on its way to offering ... as retinitis pigmentosa and age-related degeneration of the eye ... implant works for eye diseases in which healthy retinal ... eye’s photoreceptors.// These receptors convert images into electric impulses. Researchers ...
... nose can be unpleasant, but doctors say that discomfort ... decongestants if you have high blood pressure. Though they ... contain decongestants such as pseudoephedrine and phenylephrine, which doctors ... products containing such ingredients are required to list such ...
... Scientific study suggests that the much famed tanning salons, ... chances of a number of more common skin cancers. ... National Cancer Institute claims to have found a relationship ... like basal cell carcinoma, squamous cell carcinoma and melanoma. ...
... fertility found that women who experienced pleasurable sex retained more ... The best way to get pregnant is to have a ... Cathy, from the School of Psychology at Ohio University, studied ... were asked to go to a clinic within a few ...
... Researchers state that weekend alcohol flings and the stress of ... increased rate of heart attack. A 7 year study carried ... die from heart attacks on a Monday than any other ... the nexus between exorbitant drinking and coronary heart disease.//They suggested ...
Cached Medicine News:
(Date:5/16/2013)... 2013  PTC Therapeutics, Inc., today announced that it ... the U.S. Securities and Exchange Commission ("SEC") relating to ... The number of shares to be offered and the ... (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) ... book-running managers for the offering. Cowen and Company is ...
(Date:5/16/2013)... and SYDNEY , May 16, ... - ASX: HIN), a leading innovator of less invasive, miniaturized ... heart failure, today announced that CEO Doug Godshall ... Global Healthcare Conference at 11:00 a.m. EDT on Monday, May ... at the Sheraton New York Hotel. A live ...
(Date:5/16/2013)... , May 16, 2013 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for the treatment ... Richard King , President and CEO, will present a ... Sheraton New York Hotel in New York ... 2013 at 9:30 a.m. ET/6:30 a.m. PT. The ...
Breaking Medicine Technology:PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference 2AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference 3
... well as humidification, try Flo-Mist™., ,Flo-Mist™, ... continuous medication nebulizer (CMN), engineered to deliver ... ml reservoir and jet flow design allow ... medication delivery at 25 ml/hr. Particles are ...
Nebulizer Custom Kit...
... Innovators in Anesthesia and Respiratory Products, ... quality medical devices for Anesthesia and Respiratory ... manufacture products that enhance the clinician's ability ... close attention to the bottom line. , ...
... nebulizer achieves optimum lung penetration for maximum ... is 1.04-1.10 µ at 6-8 LPM. Latex-free ... ,As the world leader in airway ... assurance of proven technology by offering top ...
Medicine Products: